Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab Dose and Interval Reduction/Withdrawal in SLE
ChiCTR2100052342Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guilin Medical University
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in systemic lupus erythematosus (SLE) (4 arms), sponsored by The First Affiliated Hospital of Guilin Medical University. Primary endpoint: Time to first flare. Started Dec 2021; status: recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2100052342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052342.